Genor Biopharma Holdings Limited ( (HK:6998) ) has shared an update.
Genor Biopharma Holdings Limited has announced its intention to propose the removal of PricewaterhouseCoopers (PwC) as its auditor due to disagreements on the audit timeline for the financial year ending December 2024. The company plans to appoint Ernst & Young (EY) as the new auditor, subject to shareholder approval at the upcoming extraordinary general meeting. This change is not expected to significantly impact the annual audit or the release of financial results, and aims to maintain audit quality in the best interests of the company and its shareholders.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a company incorporated in the Cayman Islands, operating within the biopharmaceutical industry. It is listed on the Hong Kong Stock Exchange and focuses on the development and commercialization of innovative therapies, particularly in the field of oncology.
YTD Price Performance: 5.26%
Average Trading Volume: 20,382
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €113.8M
For an in-depth examination of 6998 stock, go to TipRanks’ Stock Analysis page.